Maintaining a healthy body weight through balanced nutrition and regular activity may help preserve normal GLP-1 secretion patterns
Multimodal therapy offers the best likelihood of relapse-free survival compared with any single therapy
In 2005, exenatide, marketed as Byetta, became the first GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes
D., Cornish, S
Parenteral administration is expected to dominate the market, accounting for 80% of the market share in 2026, as GLP-1 Receptor Agonists are commonly administered via injections for better absorption and efficacy
Unstained cell controls used for autofluorescence extraction were generated for each time point, culture condition (control), and metabolic inhibitor treatment (C, 2DG, O, DGO)